Progenics chronicles

Progenics chronicles

Progenics' stock has had a bumpy ride from the newsflow related to the methylnaltrexone compound it in-licensed from UR Labs in 2001. The company ended last week up 95% - gaining $6.52 to $13.40 - on FDA

Read the full 381 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE